{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:32:01Z","timestamp":1790386321666,"version":"4.1.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Isocitrate dehydrogenase 1 (<jats:italic toggle=\"yes\">IDH1<\/jats:italic>) and <jats:italic toggle=\"yes\">IDH2<\/jats:italic> mutations occur in a variety of myeloid neoplasms. Immunohistochemistry (IHC)-based direct visualization of mutant clones of hematopoietic cells can be useful for rapid diagnostic screening and for monitoring treatment response. In this study, we first evaluated the sensitivity and specificity of the IDH1 p.R132H mutation-specific antibody by IHC. All <jats:italic toggle=\"yes\">IDH1<\/jats:italic> wild type cases (n=11) and <jats:italic toggle=\"yes\">IDH1<\/jats:italic> mutant cases with a non-p.R132H mutation (n=30) were negative by IHC, demonstrating 100% antibody specificity. All the initial diagnostic specimens with <jats:italic toggle=\"yes\">IDH1<\/jats:italic> p.R132H mutation including acute myeloid leukemia (n=30), myelodysplastic syndromes (MDS) (n=10), MDS\/myeloproliferative neoplasms (MPN) (n=4), and MPN (n=5) were positive by IHC, demonstrating 100% antibody sensitivity. Both immature and mature myeloid cells showed immunoreactivity. Erythroid precursors, lymphoid cells, endothelial cells, and osteoblasts were consistently negative by IHC. We then evaluated the follow-up specimens with a known <jats:italic toggle=\"yes\">IDH1<\/jats:italic> mutation status including acute myeloid leukemia (n=23), MDS (n=2), MDS\/MPN (n=2), and MPN (n=2). Thirty-three <jats:italic toggle=\"yes\">IDH1<\/jats:italic> p.R132H mutant cases were positive by IHC and 12 <jats:italic toggle=\"yes\">IDH1<\/jats:italic> mutation negative cases were negative by IHC. However, IHC reactivity in up to 25% of bone marrow cells was noted in 8 of 20 polymerase chain reaction-negative cases, all from patients with a known history of IDH1 p.R132H mutation indicating sampling error or a sensitivity issue with molecular tests. These data indicate that IHC is a highly specific and sensitive tool to detect <jats:italic toggle=\"yes\">IDH1<\/jats:italic> p.R132H mutation in bone marrow involved by myeloid neoplasms. In addition, IDH1 p.R132H IHC also allows localization and assessment of the maturation stage of the clones carrying the mutation.<\/jats:p>","DOI":"10.1097\/pas.0000000000000970","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T20:11:18Z","timestamp":1508962278000},"page":"569-577","source":"Crossref","is-referenced-by-count":12,"title":["Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms"],"prefix":"10.1097","volume":"42","author":[{"given":"Habibe","family":"Kurt","sequence":"first","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Bueso-Ramos","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Routbort","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang V.","family":"Patel","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[{"name":"Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[{"name":"Hematopathology, Division of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4161\/cbt.4.1.1434","article-title":"The thioredoxin reductase\/thioredoxin system: novel redox targets for cancer therapy","volume":"4","author":"Biaglow","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2010.52","article-title":"Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms","volume":"24","author":"Kosmider","year":"2010","journal-title":"Leukemia"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with npm1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.26580","article-title":"Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin","volume":"118","author":"Ravandi","year":"2012","journal-title":"Cancer"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.leukres.2012.03.019","article-title":"Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group","volume":"36","author":"Nomdedeu","year":"2012","journal-title":"Leuk Res"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2010.267","article-title":"The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia","volume":"25","author":"Chou","year":"2011","journal-title":"Leukemia"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1200\/JCO.2009.27.6899","article-title":"Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor","volume":"28","author":"Wagner","year":"2010","journal-title":"J Clin Oncol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/leu.2011.298","article-title":"Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients","volume":"26","author":"Patnaik","year":"2012","journal-title":"Leukemia"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms","volume":"362","author":"Green","year":"2010","journal-title":"N Engl J Med"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/leu.2015.91","article-title":"Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms","volume":"29","author":"Molenaar","year":"2015","journal-title":"Leukemia"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/leu.2014.124","article-title":"DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies","volume":"28","author":"Im","year":"2014","journal-title":"Leukemia"},{"key":"R24-20230922","first-page":"373","article-title":"Targeting isocitrate dehydrogenase (IDH) in cancer","volume":"21","author":"Fujii","year":"2016","journal-title":"Discov Med"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10014-015-0214-8","article-title":"Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas","volume":"32","author":"Takano","year":"2015","journal-title":"Brain Tumor Pathol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10014-014-0202-4","article-title":"Specific monoclonal antibodies against IDH1\/2 mutations as diagnostic tools for gliomas","volume":"32","author":"Kato","year":"2015","journal-title":"Brain Tumor Pathol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1620\/tjem.230.103","article-title":"Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations","volume":"230","author":"Kato Kaneko","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.leukres.2010.02.014","article-title":"Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing","volume":"34","author":"Andrulis","year":"2010","journal-title":"Leuk Res"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3324\/haematol.2013.093765","article-title":"Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring","volume":"99","author":"Luthra","year":"2014","journal-title":"Haematologica"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jmoldx.2011.06.004","article-title":"Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis","volume":"13","author":"Patel","year":"2011","journal-title":"J Mol Diagn"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1750-3639.2009.00352.x","article-title":"Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors","volume":"20","author":"Capper","year":"2010","journal-title":"Brain Pathol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5414\/NP300422","article-title":"IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee","volume":"30","author":"Preusser","year":"2011","journal-title":"Clin Neuropathol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature11323","article-title":"IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics","volume":"488","author":"Sasaki","year":"2012","journal-title":"Nature"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1101\/gad.226613.113","article-title":"Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition","volume":"27","author":"Chen","year":"2013","journal-title":"Genes Dev"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2013.12.016","article-title":"Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance","volume":"14","author":"Kats","year":"2014","journal-title":"Cell Stem Cell"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0167-4781(93)90036-D","article-title":"DNA hypomethylation and differentiation in friend leukemia cell variants","volume":"1216","author":"Palitti","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/leu.2008.397","article-title":"The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells","volume":"23","author":"Flotho","year":"2009","journal-title":"Leukemia"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.V126.23.323.323","article-title":"Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1\/2 trial","volume":"126","author":"Stein","year":"2015","journal-title":"Blood"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1016\/S1470-2045(14)71140-4","article-title":"Inhibition of mutant IDH1 in acute myeloid leukaemia","volume":"16","author":"Yaqub","year":"2015","journal-title":"Lancet Oncol"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2016.04.006","article-title":"Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120","volume":"16","author":"Birendra","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2010-02-267955","article-title":"IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status","volume":"116","author":"Schnittger","year":"2010","journal-title":"Blood"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201805000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:36:32Z","timestamp":1695422192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201805000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000970","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}